Analysts Set Expectations for TVTX FY2025 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Travere Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will earn ($1.13) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.93) per share.

Travere Therapeutics (NASDAQ:TVTX) last announced its earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.01. The business had revenue of $62.90 million for the quarter, compared to the consensus estimate of $60.87 million. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The business’s revenue for the quarter was up 69.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.17) earnings per share.

TVTX has been the topic of a number of other research reports. Piper Sandler upped their target price on Travere Therapeutics from $12.00 to $22.00 and gave the company a “neutral” rating in a research note on Thursday, November 14th. Leerink Partners reaffirmed an “outperform” rating and issued a $20.00 price objective on shares of Travere Therapeutics in a research report on Tuesday, October 8th. Bank of America lifted their target price on Travere Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Barclays raised their price target on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. Finally, HC Wainwright lifted their price objective on shares of Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, January 15th. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, Travere Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $24.00.

Travere Therapeutics Stock Up 5.9 %

Travere Therapeutics stock opened at $19.46 on Wednesday. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. Travere Therapeutics has a 1-year low of $5.12 and a 1-year high of $20.33. The company’s 50-day moving average is $18.21 and its 200 day moving average is $14.72.

Insider Activity

In other Travere Therapeutics news, CAO Sandra Calvin sold 12,090 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $18.30, for a total transaction of $221,247.00. Following the sale, the chief accounting officer now owns 54,927 shares of the company’s stock, valued at approximately $1,005,164.10. The trade was a 18.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jula Inrig sold 2,066 shares of the firm’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $19.10, for a total transaction of $39,460.60. Following the completion of the transaction, the insider now directly owns 59,883 shares of the company’s stock, valued at approximately $1,143,765.30. This represents a 3.34 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 29,596 shares of company stock worth $527,262. Insiders own 4.06% of the company’s stock.

Hedge Funds Weigh In On Travere Therapeutics

Several hedge funds have recently made changes to their positions in TVTX. CWM LLC lifted its position in Travere Therapeutics by 158.5% during the 3rd quarter. CWM LLC now owns 4,999 shares of the company’s stock worth $70,000 after acquiring an additional 3,065 shares during the period. DRW Securities LLC purchased a new position in shares of Travere Therapeutics in the second quarter worth about $95,000. Quarry LP acquired a new stake in shares of Travere Therapeutics during the third quarter worth about $105,000. Forefront Analytics LLC boosted its position in Travere Therapeutics by 10.2% in the second quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock valued at $109,000 after buying an additional 1,237 shares during the last quarter. Finally, Sei Investments Co. purchased a new stake in Travere Therapeutics in the second quarter valued at approximately $117,000.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.